spacer
home > ict > summer 2021 > patient engagement in the new age of clinical trials
PUBLICATIONS
International Clinical Trials

Patient Engagement in the New Age of Clinical Trials


Digital. Decentralised. Diverse. Data rich. The modernisation of clinical trials to routinely include digital tools and decentralised approaches facilitates the inclusion of patients that are representative of clinically relevant populations, and supports collection of data from multiple sources. Routine inclusion of patients in trial design and implementation has become an expected component of today’s trials, with an even stronger aim towards achieving what matters most: getting new medicines to patients safely and efficiently.

While standards of practice are not yet defined, collaborative conversations that include all stakeholders continue to develop and refine initiatives. Beyond providing input into the planning, execution, and reporting of clinical trials, patients now expect to be engaged as full partners in their care, through more widespread adoption of master protocols and complex innovative designs. Social media provides a new outlet for amplifying patient preferences, providing another sphere for influencing both consumer and industry-wide decision-making in drug development.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
About the Author

Barbara Lopez Kunz serves as President and Global Chief Executive of DIA, driving thought leadership and innovation in therapeutic development to improve the health of people worldwide. She previously served as President of Health and Life Sciences at Battelle, one of the world’s largest R&D organisations.

Dr Courtney Granville brings over two decades of biomedical and regulatory science-related research experience to her role at DIA. As Global Associate Director Research & Scientific Programs, she provides insights, guidance, and a collaborative approach to build DIA’s research and thought leadership in support of organisations working to bring innovation and efficiency to biomedical product development.
Print this page
Send to a friend
Privacy statement
News and Press Releases

Sanofi invests $180 million equity in Owkin’s artificial intelligence and federated learning to advance oncology pipeline

Sanofi announced today an equity investment of $180 million and a new strategic collaboration with Owkin comprised of discovery and development programmes in four exclusive types of cancer, with a total payment of $90 million for three years plus additional research milestone-based payments.
More info >>

White Papers

Is Your Biobank Ready for the Challenge of Biomarker-based Research?

BioFortis

Targeted and personalized studies with well-defined patient segmentation biomarkers are becoming the norm in clinical trials. This increased interest in molecular biomarker studies necessitates a rigor and sophistication in sample management within the clinical trial context that is often not supported either by traditional clinical trial management software (CTMS), or biobanking systems.  Download our Next Generation Biobanking whitepaper and learn about how to overcome the key challenges in clinical trial sample management from working in a distributed network of partners and stakeholder to managing consents and generating scientific insights.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement